Evaluation of predictive and prognostic values of plasma interleukin-6 levels in patients with advanced hepatocellular carcinoma who received sorafenib as first-line therapy

Trial Profile

Evaluation of predictive and prognostic values of plasma interleukin-6 levels in patients with advanced hepatocellular carcinoma who received sorafenib as first-line therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Apr 2017 New trial record
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top